Industry partnership will determine the success of the transition to low-GWP pMDIs
Opinion by Darren Bromley-Davenport, Technical Manager at Orbia Fluor & Energy Materials A tightening regulatory landscape is driving the pharmaceutical…
Opinion by Darren Bromley-Davenport, Technical Manager at Orbia Fluor & Energy Materials A tightening regulatory landscape is driving the pharmaceutical…
Increasingly, generative AI is transforming how that information is analysed, summarised and shared. According to 2026 research by the Copyright…
Bringing a new drug to market is one of the most time‑consuming and costly assignments within the pharma industry. From…
While these transfers are a normal part of business, navigating them requires a strategic approach to ensure smooth and efficient…
Growth in LBP production can be attributed to well-defined regulatory pathways in regions such as the US and EU, advancements…
The brand-new edition of the 2026 Clinical Research Report examines key therapy areas and deep dives into the latest advances…
Author: Manny Vazquez, Senior Director Clinical Data Strategy, Veeva The number of data points collected in clinical trials has tripled…
This year’s congress showcased remarkable progress across multiple fronts, from next-generation immunotherapies and antibody-drug conjugates (ADCs) to the accelerating role of AI-driven…
In the fast-paced environment of pharmaceutical innovation, bioconjugation has proved to be a cornerstone technology. By enabling the precise modification…
AI is revolutionizing drug discovery with its ability to analyze vast datasets. Particularly beneficial in the early drug discovery phase,…